HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Iovance Biotherapeutics (NASDAQ: IOVA) and maintained a price target of $32.
June 03, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Iovance Biotherapeutics and maintained a price target of $32, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $32 price target by HC Wainwright & Co. suggests strong confidence in Iovance Biotherapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100